

Global Antibody Therapeutics Market Size study, by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, Polyclonal Antibody), by Route of Administration (Intravenous, Subcutaneous), by Source (Chimeric, Human, Humanized), by Disease Areas (Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, Osteology), by End User (Hospitals, Long-term Care Facilities) and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G3AC90AFC10AEN.html

Date: July 2024

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: G3AC90AFC10AEN

Abstracts

The Global Antibody Therapeutics Market is valued approximately at USD 248.79 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.89% over the forecast period 2024-2032. Antibody therapeutics represent a class of medical treatments leveraging antibodies to enhance or mimic the immune system's ability to combat diseases. With their high specificity and lower toxicity compared to conventional drugs, antibody therapeutics have emerged as effective treatments for a plethora of conditions, including cancers, autoimmune diseases, and infectious diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure globally have significantly driven the adoption of antibody therapeutics. Despite these challenges, advancements in medical technology are leading to more efficient antibody production, and the emergence of next-generation antibodies along with supportive government initiatives for cancer care are anticipated to provide substantial opportunities for market growth.

The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for



better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.

Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.

Major market players included in this report are:

AbbVie Inc.

AbCellera Biologics Inc.

Adaptimmune Therapeutics PLC


ADC Therapeutics SA

Aenova Holding GmbH

Almac Group Limited

Amgen Inc.







Human
Humanized
By Disease Areas:
Autoimmune & Inflammatory Diseases
Hematology
Immunology
Neurology
Oncology
Osteology
By End User:
Hospitals
Long-term Care Facilities
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany

France



Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022



Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.



Contents

CHAPTER 1. GLOBAL ANTIBODY THERAPEUTICS MARKET EXECUTIVE SUMMARY

- 1.1. Global Antibody Therapeutics Market Size & Forecast (2022- 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Format
 - 1.3.2. By Route of Administration
 - 1.3.3. By Source
 - 1.3.4. By Disease Areas
 - 1.3.5. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL ANTIBODY THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates



CHAPTER 3. GLOBAL ANTIBODY THERAPEUTICS MARKET DYNAMICS

- 3.1. Market Drivers
 - 3.1.1. Increasing Prevalence of Chronic Diseases
 - 3.1.2. Advancements in Medical Technology
- 3.2. Market Challenges
 - 3.2.1. High Development Costs
 - 3.2.2. Complex Regulatory Approvals
- 3.3. Market Opportunities
 - 3.3.1. Emergence of Next-Generation Antibodies
 - 3.3.2. Supportive Government Initiatives for Cancer Care

CHAPTER 4. GLOBAL ANTIBODY THERAPEUTICS MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
 - 4.1.6. Futuristic Approach to Porter's 5 Force Model
 - 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
 - 4.2.1. Political
 - 4.2.2. Economical
 - 4.2.3. Social
 - 4.2.4. Technological
 - 4.2.5. Environmental
 - 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY FORMAT 2022-2032



- 5.1. Segment Dashboard
- 5.2. Global Antibody Therapeutics Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 5.2.1. Antibody Fragment
 - 5.2.2. Bispecific Antibody
 - 5.2.3. Monoclonal Antibody
 - 5.2.4. Polyclonal Antibody

CHAPTER 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032

- 6.1. Segment Dashboard
- 6.2. Global Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 6.2.1. Intravenous
 - 6.2.2. Subcutaneous

CHAPTER 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY SOURCE 2022-2032

- 7.1. Segment Dashboard
- 7.2. Global Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 7.2.1. Chimeric
 - 7.2.2. Human
 - 7.2.3. Humanized

CHAPTER 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY DISEASE AREAS 2022-2032

- 8.1. Segment Dashboard
- 8.2. Global Antibody Therapeutics Market: Disease Areas Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 8.2.1. Autoimmune & Inflammatory Diseases
 - 8.2.2. Hematology
 - 8.2.3. Immunology
 - 8.2.4. Neurology
 - 8.2.5. Oncology



8.2.6. Osteology

CHAPTER 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY END USER 2022-2032

- 9.1. Segment Dashboard
- 9.2. Global Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 9.2.1. Hospitals
 - 9.2.2. Long-term Care Facilities

CHAPTER 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032

- 10.1. North America Antibody Therapeutics Market
 - 10.1.1. U.S. Antibody Therapeutics Market
 - 10.1.1.1. Format breakdown size & forecasts, 2022-2032
 - 10.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.1.1.3. Source breakdown size & forecasts, 2022-2032
 - 10.1.1.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.1.1.5. End User breakdown size & forecasts, 2022-2032
 - 10.1.2. Canada Antibody Therapeutics Market
 - 10.1.2.1. Format breakdown size & forecasts, 2022-2032
 - 10.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.1.2.3. Source breakdown size & forecasts, 2022-2032
 - 10.1.2.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.1.2.5. End User breakdown size & forecasts, 2022-2032
- 10.2. Europe Antibody Therapeutics Market
 - 10.2.1. UK Antibody Therapeutics Market
 - 10.2.1.1. Format breakdown size & forecasts, 2022-2032
 - 10.2.1.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.2.1.3. Source breakdown size & forecasts, 2022-2032
 - 10.2.1.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.2.1.5. End User breakdown size & forecasts, 2022-2032
 - 10.2.2. Germany Antibody Therapeutics Market
 - 10.2.2.1. Format breakdown size & forecasts, 2022-2032
 - 10.2.2.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.2.2.3. Source breakdown size & forecasts, 2022-2032
 - 10.2.2.4. Disease Areas breakdown size & forecasts, 2022-2032



- 10.2.2.5. End User breakdown size & forecasts, 2022-2032
- 10.2.3. France Antibody Therapeutics Market
 - 10.2.3.1. Format breakdown size & forecasts, 2022-2032
 - 10.2.3.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.2.3.3. Source breakdown size & forecasts, 2022-2032
 - 10.2.3.4. Disease Areas breakdown size & forecasts, 2022-2032
- 10.2.3.5. End User breakdown size & forecasts, 2022-2032
- 10.2.4. Spain Antibody Therapeutics Market
 - 10.2.4.1. Format breakdown size & forecasts, 2022-2032
 - 10.2.4.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.2.4.3. Source breakdown size & forecasts, 2022-2032
 - 10.2.4.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.2.4.5. End User breakdown size & forecasts, 2022-2032
- 10.2.5. Italy Antibody Therapeutics Market
 - 10.2.5.1. Format breakdown size & forecasts, 2022-2032
 - 10.2.5.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.2.5.3. Source breakdown size & forecasts, 2022-2032
 - 10.2.5.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.2.5.5. End User breakdown size & forecasts, 2022-2032
- 10.2.6. Rest of Europe Antibody Therapeutics Market
 - 10.2.6.1. Format breakdown size & forecasts, 2022-2032
 - 10.2.6.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.2.6.3. Source breakdown size & forecasts, 2022-2032
 - 10.2.6.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.2.6.5. End User breakdown size & forecasts, 2022-2032
- 10.3. Asia-Pacific Antibody Therapeutics Market
 - 10.3.1. China Antibody Therapeutics Market
 - 10.3.1.1. Format breakdown size & forecasts, 2022-2032
 - 10.3.1.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.3.1.3. Source breakdown size & forecasts, 2022-2032
 - 10.3.1.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.3.1.5. End User breakdown size & forecasts, 2022-2032
 - 10.3.2. India Antibody Therapeutics Market
 - 10.3.2.1. Format breakdown size & forecasts, 2022-2032
 - 10.3.2.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.3.2.3. Source breakdown size & forecasts, 2022-2032
 - 10.3.2.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.3.2.5. End User breakdown size & forecasts, 2022-2032
 - 10.3.3. Japan Antibody Therapeutics Market



- 10.3.3.1. Format breakdown size & forecasts, 2022-2032
- 10.3.3.2. Route of Administration breakdown size & forecasts, 2022-2032
- 10.3.3.3. Source breakdown size & forecasts, 2022-2032
- 10.3.3.4. Disease Areas breakdown size & forecasts, 2022-2032
- 10.3.3.5. End User breakdown size & forecasts, 2022-2032
- 10.3.4. Australia Antibody Therapeutics Market
- 10.3.4.1. Format breakdown size & forecasts, 2022-2032
- 10.3.4.2. Route of Administration breakdown size & forecasts, 2022-2032
- 10.3.4.3. Source breakdown size & forecasts, 2022-2032
- 10.3.4.4. Disease Areas breakdown size & forecasts, 2022-2032
- 10.3.4.5. End User breakdown size & forecasts, 2022-2032
- 10.3.5. South Korea Antibody Therapeutics Market
- 10.3.5.1. Format breakdown size & forecasts, 2022-2032
- 10.3.5.2. Route of Administration breakdown size & forecasts, 2022-2032
- 10.3.5.3. Source breakdown size & forecasts, 2022-2032
- 10.3.5.4. Disease Areas breakdown size & forecasts, 2022-2032
- 10.3.5.5. End User breakdown size & forecasts, 2022-2032
- 10.3.6. Rest of Asia Pacific Antibody Therapeutics Market
 - 10.3.6.1. Format breakdown size & forecasts, 2022-2032
 - 10.3.6.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.3.6.3. Source breakdown size & forecasts, 2022-2032
 - 10.3.6.4. Disease Areas breakdown size & forecasts, 2022-2032
- 10.3.6.5. End User breakdown size & forecasts, 2022-2032
- 10.4. Latin America Antibody Therapeutics Market
 - 10.4.1. Brazil Antibody Therapeutics Market
 - 10.4.1.1. Format breakdown size & forecasts, 2022-2032
 - 10.4.1.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.4.1.3. Source breakdown size & forecasts, 2022-2032
 - 10.4.1.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.4.1.5. End User breakdown size & forecasts, 2022-2032
 - 10.4.2. Mexico Antibody Therapeutics Market
 - 10.4.2.1. Format breakdown size & forecasts, 2022-2032
 - 10.4.2.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.4.2.3. Source breakdown size & forecasts, 2022-2032
 - 10.4.2.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.4.2.5. End User breakdown size & forecasts, 2022-2032
 - 10.4.3. Rest of Latin America Antibody Therapeutics Market
 - 10.4.3.1. Format breakdown size & forecasts, 2022-2032
 - 10.4.3.2. Route of Administration breakdown size & forecasts, 2022-2032



- 10.4.3.3. Source breakdown size & forecasts, 2022-2032
- 10.4.3.4. Disease Areas breakdown size & forecasts, 2022-2032
- 10.4.3.5. End User breakdown size & forecasts, 2022-2032
- 10.5. Middle East & Africa Antibody Therapeutics Market
 - 10.5.1. Saudi Arabia Antibody Therapeutics Market
 - 10.5.1.1. Format breakdown size & forecasts, 2022-2032
 - 10.5.1.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.5.1.3. Source breakdown size & forecasts, 2022-2032
 - 10.5.1.4. Disease Areas breakdown size & forecasts. 2022-2032
 - 10.5.1.5. End User breakdown size & forecasts, 2022-2032
 - 10.5.2. South Africa Antibody Therapeutics Market
 - 10.5.2.1. Format breakdown size & forecasts, 2022-2032
 - 10.5.2.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.5.2.3. Source breakdown size & forecasts, 2022-2032
 - 10.5.2.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.5.2.5. End User breakdown size & forecasts, 2022-2032
 - 10.5.3. Rest of Middle East & Africa Antibody Therapeutics Market
 - 10.5.3.1. Format breakdown size & forecasts, 2022-2032
 - 10.5.3.2. Route of Administration breakdown size & forecasts, 2022-2032
 - 10.5.3.3. Source breakdown size & forecasts, 2022-2032
 - 10.5.3.4. Disease Areas breakdown size & forecasts, 2022-2032
 - 10.5.3.5. End User breakdown size & forecasts, 2022-2032

CHAPTER 11. COMPETITIVE INTELLIGENCE

- 11.1. Key Company SWOT Analysis
 - 11.1.1. AbbVie Inc.
 - 11.1.2. AbCellera Biologics Inc.
 - 11.1.3. Adaptimmune Therapeutics PLC.
- 11.2. Top Market Strategies
- 11.3. Company Profiles
 - 11.3.1. AbbVie Inc.
 - 11.3.1.1. Key Information
 - 11.3.1.2. Overview
 - 11.3.1.3. Financial (Subject to Data Availability)
 - 11.3.1.4. Product Summary
 - 11.3.1.5. Market Strategies
 - 11.3.2. AbCellera Biologics Inc.
 - 11.3.3. Adaptimmune Therapeutics PLC.



- 11.3.4. ADC Therapeutics SA
- 11.3.5. Aenova Holding GmbH
- 11.3.6. Almac Group Limited
- 11.3.7. Amgen Inc.
- 11.3.8. Antikor Biopharma
- 11.3.9. Argenx SE
- 11.3.10. Astellas Pharma Inc.
- 11.3.11. AstraZeneca PLC
- 11.3.12. Baxter International Inc.
- 11.3.13. Bayer AG
- 11.3.14. Becton, Dickinson and Company
- 11.3.15. Bio-Rad Laboratories, Inc.

CHAPTER 12. RESEARCH PROCESS

- 12.1. Research Process
 - 12.1.1. Data Mining
 - 12.1.2. Analysis
 - 12.1.3. Market Estimation
 - 12.1.4. Validation
 - 12.1.5. Publishing
- 12.2. Research Attributes



List Of Tables

LIST OF TABLES

- TABLE 1. Global Antibody Therapeutics market, report scope
- TABLE 2. Global Antibody Therapeutics market estimates & forecasts by Region 2022-2032 (USD Billion)
- TABLE 3. Global Antibody Therapeutics market estimates & forecasts by Format 2022-2032 (USD Billion)
- TABLE 4. Global Antibody Therapeutics market estimates & forecasts by Route of Administration 2022-2032 (USD Billion)
- TABLE 5. Global Antibody Therapeutics market estimates & forecasts by Source 2022-2032 (USD Billion)
- TABLE 6. Global Antibody Therapeutics market estimates & forecasts by Disease Areas 2022-2032 (USD Billion)
- TABLE 7. Global Antibody Therapeutics market estimates & forecasts by End User 2022-2032 (USD Billion)
- TABLE 8. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 9. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 10. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 11. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 12. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 13. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 14. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 15. U.S. Antibody Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
- TABLE 16. U.S. Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
- TABLE 17. U.S. Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
- TABLE 18. Canada Antibody Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)



TABLE 19. Canada Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)

TABLE 20. Canada Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)



List Of Figures

LIST OF FIGURES

- FIG 1. Global Antibody Therapeutics market, research methodology
- FIG 2. Global Antibody Therapeutics market, market estimation techniques
- FIG 3. Global market size estimates & forecast methods.
- FIG 4. Global Antibody Therapeutics market, key trends 2023
- FIG 5. Global Antibody Therapeutics market, growth prospects 2022-2032
- FIG 6. Global Antibody Therapeutics market, porters 5 force model
- FIG 7. Global Antibody Therapeutics market, PESTEL analysis
- FIG 8. Global Antibody Therapeutics market, value chain analysis
- FIG 9. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 10. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 11. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 12. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 13. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
- FIG 14. Global Antibody Therapeutics market, regional snapshot 2022 & 2032
- FIG 15. North America Antibody Therapeutics market 2022 & 2032 (USD Billion)
- FIG 16. Europe Antibody Therapeutics market 2022 & 2032 (USD Billion)
- FIG 17. Asia pacific Antibody Therapeutics market 2022 & 2032 (USD Billion)
- FIG 18. Latin America Antibody Therapeutics market 2022 & 2032 (USD Billion)
- FIG 19. Middle East & Africa Antibody Therapeutics market 2022 & 2032 (USD Billion)
- FIG 20. Global Antibody Therapeutics market, company market share analysis (2023)



I would like to order

Product name: Global Antibody Therapeutics Market Size study, by Format (Antibody Fragment,

Bispecific Antibody, Monoclonal Antibody, Polyclonal Antibody), by Route of

Administration (Intravenous, Subcutaneous), by Source (Chimeric, Human, Humanized), by Disease Areas (Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, Osteology), by End User (Hospitals, Long-term Care Facilities) and

Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G3AC90AFC10AEN.html

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G3AC90AFC10AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms



& Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970